# Evolocumab Compared to LDL-C Apheresis in Patients Receiving LDL-C Apheresis Prior to Study Enrollment

> **NCT02585895** · PHASE3 · COMPLETED · sponsor: **Amgen** · enrollment: 39 (actual)

## Conditions studied

- Hypercholesterolemia

## Interventions

- **BIOLOGICAL:** Evolocumab
- **PROCEDURE:** Low-density Lipoprotein Cholesterol (LDL-C) Apheresis

## Key facts

- **NCT ID:** NCT02585895
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-12-21
- **Primary completion:** 2016-09-01
- **Final completion:** 2017-01-20
- **Target enrollment:** 39 (ACTUAL)
- **Last updated:** 2022-11-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02585895

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02585895, "Evolocumab Compared to LDL-C Apheresis in Patients Receiving LDL-C Apheresis Prior to Study Enrollment". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02585895. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*